Welcome to our dedicated page for Artivion news (Ticker: AORT), a resource for investors and traders seeking the latest updates and insights on Artivion stock.
Artivion, Inc. (NYSE: AORT) is a medical device company focused on cardiac and vascular surgery, particularly the treatment of aortic diseases. News about Artivion frequently centers on its aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues, as well as clinical and regulatory developments related to these products.
Investors and clinicians following AORT news can expect regular updates on quarterly financial results, including revenue trends for key product lines such as stent grafts, On-X valves, BioGlue surgical sealant and preservation services. Earnings releases often discuss constant currency growth, adjusted EBITDA and non-GAAP performance metrics, along with management’s commentary on business momentum and financial outlook.
Artivion’s news flow also highlights progress in its aortic disease clinical programs. Recent announcements have covered the PERSEVERE and PROTECT trials for the AMDS Hybrid Prosthesis, including late-breaking data presented at major cardiothoracic surgery meetings, as well as the ARTIZEN pivotal trial evaluating the Arcevo LSA Hybrid Stent Graft System for acute and chronic aortic arch pathologies. These updates provide insight into the clinical performance and potential regulatory pathways for the company’s aortic technologies.
Additional news items may include participation in healthcare and medtech investor conferences, amendments to credit facilities, real estate transactions related to manufacturing capacity, and executive leadership changes disclosed through SEC filings and press releases. For market participants tracking AORT, this news page offers a centralized view of Artivion’s financial communications, clinical milestones and corporate developments over time.
Artivion, Inc. (NYSE: AORT) has announced its participation in the UBS 2022 Global Healthcare Conference on May 23, 2022, at the Lotte New York Palace, with a fireside chat scheduled for 2:45 p.m. ET. A live webcast will be accessible through Artivion's website, and an archived version will be available for 90 days. Based in Atlanta, Georgia, Artivion develops solutions for cardiac and vascular surgeons treating aortic diseases, offering products like aortic stent grafts and On-X mechanical heart valves.
Artivion, Inc. (NYSE: AORT) reported first quarter 2022 revenues of $77.2 million, up 8.6% from Q1 2021 on a GAAP basis and 11.2% on a non-GAAP constant currency basis. Key growth drivers included 34% growth in aortic stent grafts and 11% in On-X products. The company also saw remarkable overseas performance with 39% growth in Asia Pacific and 93% in Latin America. Despite a net loss of $3.4 million, progress in product development and an optimistic revenue outlook of 9% to 11% growth for 2022 were highlighted by CEO Pat Mackin.
Artivion, Inc. (NYSE: AORT) has announced that it will release its first quarter 2022 financial results on May 5, 2022, after market close. A teleconference and live webcast will follow at 4:30 p.m. ET, hosted by CEO Pat Mackin. Investors can participate in the teleconference by dialing 201-689-8261. A replay will be available post-event. Artivion specializes in cardiac and vascular solutions for aortic diseases, with products available in over 100 countries. For more details, visit www.artivion.com.
Artivion, Inc. (NYSE: AORT) announced its participation in the 21st Annual Needham Virtual Healthcare Conference on April 14, 2022, at 9:30 a.m. ET. The virtual fireside chat will be accessible via Artivion's website, with an archived version available for 90 days. Artivion focuses on innovative solutions for cardiac and vascular surgery, specifically targeting aortic diseases. Its product range includes aortic stents, surgical sealants, mechanical heart valves, and human tissues, sold in over 100 countries globally.
Artivion, Inc. (NYSE: AORT) has released its inaugural Corporate Responsibility Report detailing its Environmental, Social, and Governance (ESG) initiatives. Key highlights include efforts to reduce their carbon footprint, promote diversity, equity, and inclusion in the workplace, and improve Board-level diversity. The report underlines the company's commitment to sustainable practices and enhancing stakeholder engagement. CEO Pat Mackin emphasized the importance of these initiatives in fulfilling their mission to deliver innovative cardiac technologies globally.
Artivion, a leader in cardiac and vascular surgery, announced an Investor & Analyst Day set for March 23, 2022, in New York City. The event, starting at 9:00 AM ET, will feature management presentations and discussions from cardiac and vascular surgeons focusing on aortic disease. Attendees can expect insights into Artivion's product portfolio, market strategies, and financial performance. A live webcast will be available on Artivion’s website, with archived access post-event. Registration for in-person attendance is required by March 18, 2022.
Artivion, Inc. (NYSE: AORT) will participate in the Oppenheimer 32nd Annual Healthcare Conference on March 16, 2022, with a virtual fireside chat starting at 2:40 p.m. ET. Interested parties can access a live webcast on the company’s website at www.artivion.com. An archived version will be available for 90 days following the event. Headquartered in Atlanta, Georgia, Artivion specializes in solutions for aortic diseases, offering products in over 100 countries.
Artivion reported a record revenue of $79.4 million for Q4 2021, a 16.9% increase from Q4 2020. Full-year revenue reached $298.8 million, marking an 18.0% increase year-over-year. Despite growth, the company faced a net loss of ($20.1 million) in Q4 and ($14.8 million) for 2021. Artivion anticipates a 9.0% to 11.0% revenue growth in 2022, targeting revenues between $319.0 million and $325.0 million. Key developments include FDA approvals and advancements in clinical trials, underscoring the company's commitment to innovation in cardiac and vascular surgery.
Artivion, Inc. (NYSE: AORT) announced that its fourth quarter and full year 2021 financial results will be released on February 17, 2022, after market close. A teleconference and live webcast will occur at 4:30 p.m. ET to discuss these results, hosted by Pat Mackin, the company’s CEO. The financial report is expected to include comprehensive statistics reflecting Artivion's performance over the year. Investors can access the live call and a replay through the company's Investor Relations website.
Artivion (NYSE: AORT) announced the publication of results from the PROACT clinical trial in The Annals of Thoracic Surgery, focusing on the On-X mechanical mitral valve replacement. The trial demonstrated that patients could safely be managed with lower-intensity warfarin and aspirin, enhancing anticoagulation management post-surgery. Presented at the Society of Thoracic Surgeons' Annual Meeting, the findings could influence practice guidelines significantly. Ongoing trials aim to assess the safety of apixaban for patients with On-X aortic valves.
FAQ
What is the current stock price of Artivion (AORT)?
What is the market cap of Artivion (AORT)?
